Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Onyx Biotec Ltd. stands out in the peer comparison, primarily due to its lack of financial metrics, which positions it differently from its peers. Companies like Sun Pharmaceutical and Dr. Reddy's Laboratories demonstrate strong profitability and growth metrics, while Divi's Laboratories shows some weaknesses in growth despite solid margins. Overall, while Onyx Biotec lacks operational performance indicators, peers provide a clearer picture of sector dynamics with distinct leaders and laggards.
Strong revenue growth (YoY 13.28%) and low PE ratio (23.73), indicating good value and profitability.
Leads in profitability with a high ROE of 16.13% and EPS growth of 45.55%.
High profitability metrics and solid growth trajectory with an EPS increase of 68.07%.